Approved July of 2012
Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA). EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles.
Vascepa is specifically approved as an adjunct to diet to reduce triglyceride levels in adult patients with severe (=500 mg/dL) hypertriglyceridemia.
Vascepa is supplied as a tablet for oral administration. The recommended dose is 4 grams per day taken as two capsules twice daily with food.
The FDA approval of Vascepa was based on a randomized, placebo controlled, double-blind, parallel-group study in 151 subjects with severe hypertriglyceridemia. Baseline TG levels were between 500 and 2,000 mg/dL. The subjects received Vascepa 4mg per day for 12 weeks. Vascepa significantly reduced median TG (p< 0.001), VLDL-C (p< 0.05) and Apo B (p< 0.05) levels from baseline relative to placebo.
Adverse events associated with the use of Vascepa may include, but are not limited to, the following:
Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA). EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased ß-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.
For additional information regarding Vascepa or hypertriglyceridemia, please visit the Vascepa web page.
The Vascepa (icosapent ethyl) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.